Horizons Ventures and Sofinnova Partners completed a $35m Series C funding round in Synthace.

Horizons Ventures and Sofinnova Partners, two venture capital firms, completed a $35m Series C funding round in Synthace, a life sciences software company. “Synthace’s R&D cloud platform is helping life scientists completely change the way they develop new cures and therapeutics to solve humanity’s most pressing problems. But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources,” Guy Levy-Yurista, Synthace CEO.